2023 has brought major changes in the clinical research technology industry. As research sites face a backlog of clinical trials, they’re becoming more selective with which studies they take on.

凤凰城 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) 周二宣布，世界卫生组织 (WHO)已批准olastrocel作为其主要疗法CELZ-201活性细胞物质的国际非专有名称。这家目前市值仅为928万美元、股价为2.51美元的微型生物科技公司，近几个月来股价波动显著。

The Dr. Zachary Solomon Medical Tech Grant today announced a national call for applications from undergraduate students ...

Fiza Shaukat is a native of Pakistan living in the United States. As a biomedical engineer, she was eager to improve her country’s medical devices and digital health strategies. She approached us in ...

In this issue: 2026 forecast for the medtech industry, highlights from MEDICA 2025, Estonia's digital health DNA, and more ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...

PHOENIX, Sept. 19, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative ...

Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets ...

CELZ-201-DDT is a proprietary allogeneic regenerative therapy designed to target the underlying pathology of DDD. Administered via ultrasound-guided injection, it offers a minimally invasive, ...

Winston Salem, NC, June 20, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announced the appointment of Andrew Kraus as Chief Technology Officer. In this role, Kraus ...

Clinical research sites have faced unprecedented challenges in 2022. The resignation rate for healthcare workers continued to increase throughout 2021 and early 2022, reducing staff numbers to the ...